Core Insights - WaterPure International, Inc. is positioned for accelerated global growth through an updated business plan, an expanded management team, and upcoming R&D and manufacturing initiatives [1] Financial Performance - The company reported a net income of $140,587 for the year 2025, primarily due to the cancellation of debt [2] Management Team Expansion - WaterPure has updated its corporate website to reflect its new business plan and expanded leadership team, including the appointments of Jeff Giordano to the Board of Directors and Alex Michaels to the Advisory Board [3] Leadership Expertise - Jeff Giordano brings over 25 years of experience in corporate leadership, strategic planning, and capital markets, with a focus on driving shareholder value through restructuring and growth initiatives [4] - Alex Michaels has a strong background in business development and supply chain optimization, with experience in project management and securing non-dilutive financing for growth-stage ventures [5] Strategic Initiatives - The company aims to deliver sustainable, safe, and accessible water globally, with plans for a new North American R&D center and potential manufacturing facilities in India and Europe [6] - WaterPure anticipates entering into agreements to capitalize on these opportunities by the end of fiscal year 2026 [6] Company Mission - WaterPure International is dedicated to providing innovative, sustainable solutions for safe drinking water worldwide, focusing on advanced water purification systems for various applications, including disaster relief and underserved communities [8]

Group 1 - All 22 banks successfully passed the Federal Reserve's 2025 stress test, indicating strong financial health amidst macroeconomic uncertainty [1] - The positive results from the stress test are likely to boost investor confidence in both the economy and the banking sector [1]

Core Viewpoint - The article discusses the longstanding belief that there is a trade-off between sustainability and safety in the use of recycled materials, particularly in carbon black and flame-retardant plastics [1] Group 1 - The industry has been led to believe that choosing recycled materials necessitates a compromise in performance [1]

LONDON, UK / ACCESS Newswire / September 19, 2025 / TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BP2C3V08 Issuer Name GENFLOW BIOSCIENCES PLC UK or Non-UK Issuer UK 2. ...

Core Viewpoint - Roche announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of a subcutaneous formulation of Lunsumio (mosunetuzumab) for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, with a final decision expected from the European Commission soon [1][2]. Group 1: Product Details - Lunsumio is the first approved CD20xCD3 T-cell engaging bispecific antibody, showing high and durable response rates with a favorable safety profile in third-line or later follicular lymphoma [2][7]. - The subcutaneous formulation of Lunsumio has demonstrated pharmacokinetic non-inferiority compared to intravenous administration, with a low rate of cytokine release syndrome at 29.8% [2][6]. - The overall response rate (ORR) for patients treated with the subcutaneous formulation was 74.5%, and the complete response (CR) rate was 58.5%, with a median duration of CR at 20.8 months [6][7]. Group 2: Treatment Administration - The subcutaneous administration of Lunsumio can significantly reduce treatment administration time to approximately one minute, compared to 2-4 hours for intravenous infusion, while maintaining the same dosing schedule [2][7]. - Lunsumio is designed for a fixed duration of approximately 6-12 months, depending on patient response, allowing for a target end date and potential treatment-free periods [2][7]. Group 3: Clinical Study Information - The recommendation is based on the primary analysis of the phase II GO29781 study, which evaluated the safety, efficacy, and pharmacokinetics of Lunsumio administered both intravenously and subcutaneously [5][6]. - The GO29781 study is a multicenter, open-label, dose-escalation and expansion study focusing on relapsed or refractory B-cell non-Hodgkin lymphoma [5]. Group 4: Market Position and Future Plans - Lunsumio, along with Columvi (glofitamab), is part of Roche's leading CD20xCD3 bispecific antibody portfolio, with ongoing exploration of new formulations and combinations across various disease areas [4][10]. - Roche is committed to improving patient experience and providing diverse treatment options to meet healthcare system needs [4][10].

Ra’anana, Israel, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced the submission of its full pre-submission (Pre-Sub) package to the U.S. Food and Drug Administration (FDA) for its PL-14 product, designed to help individuals suffering from nasal allergies. The submission includes comprehensive documentation covering manufacturing plans, clinical development strategies, ...

All 22 banks passed the Federal Reserve's 2025 stress test with flying colors, showing their financial strength amidst macro uncertainty. This likely gave investors more confidence in the economy and the bank sector, especially with manyContributing analyst to the iREIT+Hoya Capital investment group. The Dividend Collectuh is not a registered investment professional nor financial advisor and these articles should not be taken as financial advice. This is for educational purposes only and I encourage everyon ...

Lunsumio provides high and long-lasting response rates, with approximately two-thirds of patients with a complete response in remission after four years1Subcutaneous Lunsumio has potential to substantially reduce treatment administration time with an approximately one minute injection, compared with 2-4 hours IV infusionIf approved, Lunsumio would be the first treatment available for people with follicular lymphoma after two or more lines of systemic therapy, which is both fixed-duration and subcutaneously ...

Intel's (NASDAQ:INTC) deal with Nvidia (NASDAQ:NVDA) to co-develop PC and data center chips could have major implications for Astera Labs (NASDAQ:ALAB), but it's unclear exactly what they are at this point, Morgan Stanley said. “While Intel was not listed on the ...

Macquarie Asset Management, an investment management company, released its “Macquarie Core Equity Fund” investor letter for the second quarter of 2025. A copy of the letter can be downloaded here. The US large-cap equity market surged in Q2 2025, with the S&P 500® Index rising 10.94%. The equity market’s strength was due to reduced concerns over the possibility of President Trump quickly imposing harsh tariffs. Later, the administration put a pause on the tariff implementation. In this environment, the Macq ...